Cargando…
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and Drug Administration–sponsored Think Tank Meeting...
Ejemplares similares
-
Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework
por: Skottheim Rusten, Ine, et al.
Publicado: (2021) -
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018) -
Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies
por: Delaunois, Annie, et al.
Publicado: (2021) -
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19
por: Delaunois, Annie, et al.
Publicado: (2021) -
Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti‐seizure medication: Levetiracetam case study
por: Delaunois, Annie, et al.
Publicado: (2023)